title: [Research progress of targeted therapy in non-small cell lung cancer brain metastases].
abstract: Lung cancer is characterized by the highest incidence of solid tumor-related brain metastases, which are reported the incidence ranged 20% to 65%. This is also one of the reasons why it can cause significant mortality. Molecular targeted therapy plays a major role in the management of brain metastases in lung cancer. Targeted agents have become the novel methods for the treatment of lung cancer with brain metastases beyond the whole brain radiation therapy, stereotactic radiosurgery and chemotherapy. Recently, more and more studies and trials laid emphasis on the targeted agents for non-small cell lung cancer (NSCLC) brain metastases treatment. The key point is the efficacy and safety. In this paper, the targeted treatments of NSCLC brain metastases were summarized.
authors.affiliation: Deportment of Oncology, Shanghai Pulmonary Hospital, Shanghai 200065, China.
authors.forename: Tao
authors.initials: T
authors.lastname: Jiang
authors.affiliation: Deportment of Oncology, Shanghai Pulmonary Hospital, Shanghai 200065, China.
authors.forename: Caicun
authors.initials: C
authors.lastname: Zhou
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D035843:Biomedical Research / Q000379:methods / Q000639:trends; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D058990:Molecular Targeted Therapy / Q000379:methods* / Q000639:trends; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors